English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

At the turn of the century, the emerging field of pharmacogenomics prompted sobering examinations of the efficiency and effectiveness of healthcare. An article published in 2001 in Trends in Molecular Medicine, for example, showed that treatments for six common diseases helped only 25–62% of the patients who receive them, depending on the disease in question [1]. By 2005, however, National Institutes of Health (MD, USA) Director Francis S Collins, who was then serving as the Director of the National Human Genome Research Institute (MD, USA), had published an op-ed in The Boston Globe suggesting that an emerging field called personalized medicine, defined by the use of diagnostic tests to help target prevention and treatment strategies to only those patients who will benefit from them, would inform more precise and effective interventions that address the root causes of devastating human diseases [2]. Recognizing the continued significance of these laudable goals for the future of medicine, the Personalized Medicine Coalition, which represents the perspectives of over 220 member institutions from every sector of the healthcare ecosystem, organized The 15th Annual Personalized Medicine Conference at Harvard Medical School on 13–14 November 2019, to consider the regulatory, reimbursement and clinical adoption challenges facing personalized medicine today. Participants concluded that personalized medicine has begun to deliver improved care by linking more sophisticated diagnostics and more effective therapies. They also acknowledged that its continued advancement requires system-wide consideration, which is far from easy in the context of today’s silo-based healthcare systems. Participants maintained that by collaborating with one another in entirely new ways, disparate stakeholders can leverage the tools underpinning personalized medicine to improve patient care and make better use of healthcare resources.

A consensus on collaboration: reviewing the 15th Annual Personalized Medicine Conference at Harvard Medical School